Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG (TICE strain)
- Development stage
- Approved
- Lead developer
- University of Illinois
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravesical, Percutaneous
01
Overview
BCG (TICE strain), marketed as TICE® BCG or OncoTICE, is a live attenuated bacterial immunotherapy derived from the Bacillus of Calmette and Guérin (BCG) strain of Mycobacterium bovis. The TICE strain was originally developed at the University of Illinois from a strain that originated at the Pasteur Institute. It is administered intravesically (directly into the bladder) and works as an immunostimulant, triggering a local immune response that targets bladder cancer cells. Each vial contains 1 to 8 × 10⁸ colony forming units (CFU), equivalent to approximately 50 mg wet weight, in a freeze-dried preparation. BCG (TICE strain) is used for the treatment of non-muscle invasive bladder cancer (NMIBC), particularly in high-risk patients, and is considered the gold standard adjuvant intravesical treatment for intermediate- and high-risk NMIBC. In the BCG-TIME trial (sponsored by Queen's University), it is being evaluated both as a monotherapy and in combination with intravesical gemcitabine in elderly patients with high-risk NMIBC, alongside a novel biomarker assessment. The drug is a biologic (live bacterial preparation), with its biological target being the host immune system — specifically stimulating innate and adaptive immune responses within the bladder to prevent tumor recurrence and progression.
- Brand names
- OncoTICETICE BCG
- Other names
- BCG LiveBCG live (Tice strain)Bacillus Calmette-Guerin (TICE strain)Mycobacterium bovis BCG (TICE strain)bacillus calmette-guerinbacillus calmette-guerin, live, Tice strain
02
Targets
ITGA5:ITGB1 (Integrin α5β1)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on BCG (TICE strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG (TICE strain).